Darovasertib data are promised for the last week of March.
ApexOnco Front Page
Recent articles
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
The company is setting up another battle with Bristol Myers Squibb, while Amgen has different plans.
Genmab’s remarkably bold acquisition raises more questions about Sutro, a key FRα rival of ProfoundBio.
April will see the first big scientific meeting of the year, and could herald important data from Immutep and GSK.
The group will need to wait for more data with its neoantigen immunotherapy Granite, but cash is running short.
A roundup of the first quarter's key oncology drug approvals and rejections.
A $44m up-front for the tumour-activated IL-12 XTX301 will help keep Xilio going until 2025.